The landscape of obesity drug sales in India is undergoing a fundamental shift as the arrival of lower-cost generics begins to challenge the dominance of premium branded therapies. While Eli Lilly’s Mounjaro currently maintains its position as the top-selling weight-loss and diabetes medication in the country, the recent patent expiry of semaglutide has opened the door for a wave of affordable alternatives that are rapidly widening patient access.
For many patients, the barrier to accessing GLP-1 receptor agonists—the class of drugs that includes both tirzepatide (Mounjaro) and semaglutide (Ozempic, Wegovy)—has long been the prohibitive cost. The introduction of generic versions has disrupted this dynamic, driving some prices down by as much as 90 percent and forcing established pharmaceutical giants to recalibrate their pricing strategies to remain competitive.
This transition reflects a broader trend in Indian healthcare: the rapid movement from high-cost, imported innovation to locally manufactured, affordable care. As the market expands, the focus is shifting from mere availability to the balance between accessibility and the prevention of medication misuse.
Market Leadership and the Generic Pressure
Recent data from PharmaTrac, a research arm of Pharmarack, reveals that Mounjaro recorded sales of Rs 114 crore in March. While it remains the market leader, this figure represents a notable dip from the Rs 135 crore recorded in February, suggesting that the “blockbuster” status of the drug is facing its first real test in the Indian market.
Mounjaro continues to be the most expensive option in its class, with starting weekly doses priced at Rs 3,581. In contrast, Novo Nordisk, the Danish manufacturer of semaglutide, has seen a more stable, albeit smaller, market presence. Its branded portfolio—which includes Ozempic, Wegovy, and Rybelsus—reported combined sales of Rs 45 crore in March, a marginal decline of only Rs 2 crore from the previous month.
| Therapy/Brand | March Sales | Pricing Position | Trend |
|---|---|---|---|
| Mounjaro (Eli Lilly) | Rs 114 Crore | Premium (Rs 3,581/week) | Declining Value Share |
| Novo Nordisk Portfolio | Rs 45 Crore | Mid-Tier (Rs 1,415/week) | Resilient Share |
| Generic Semaglutide | Rapid Growth | Low-Cost (Up to 90% off) | Expanding Volume |
The broader GLP-1 receptor agonist market reached nearly Rs 1,600 crore in March, signaling a massive surge in demand for therapies that mimic gut hormones to regulate blood sugar and suppress appetite. These medications are increasingly critical in India, where the prevalence of obesity and type 2 diabetes continues to climb.
The Rise of Local Generic Manufacturers
The expiration of the semaglutide patent on March 20 triggered an immediate response from India’s pharmaceutical sector. Nearly 15 different versions of the drug, including both injectable and oral formulations, have been launched by industry leaders such as Sun Pharma, Zydus Lifesciences, and Dr Reddy’s Laboratories.
Ahmedabad-based Torrent Pharmaceuticals has emerged as a particularly aggressive early mover. Its brands, Semalix and Sembolic, managed to capture approximately 3 percent of the market within just 10 days of their launch. This rapid adoption is attributed to a combination of aggressive pricing and a robust distribution network.
According to Dr. Rajiv Kovil, a Mumbai-based specialist in diabetology and metabolic diseases, Torrent’s success is rooted in its variety of delivery methods. “Torrent’s edge lies in its full-spectrum – oral, reusable, and disposable formats backed by decades of legacy, strong equity, deep penetration and execution discipline,” Dr. Kovil noted.
Clinical Preferences and Regulatory Guardrails
While oral versions of semaglutide have been available since the introduction of Rybelsus in 2022, there is a clear preference among both prescribers and patients for injectables. Sales volumes for injectable semaglutide more than doubled in a single month, jumping from 63,000 units in February to 143,000 units in March. This surge pushed value sales from Rs 24 crore to Rs 58 crore in the same period.
To defend its territory against the generic tide, Novo Nordisk has slashed the prices of Ozempic and Wegovy, bringing the effective daily cost down to Rs 202, or roughly Rs 1,415 per week.
But, the democratization of these powerful medications has raised alarms regarding off-label use and aggressive marketing. Because these drugs are highly effective for weight loss, there is a significant risk of them being used as “cosmetic” tools rather than medical treatments for obesity or diabetes.
In response, the Central Drugs Standard Control Organisation (CDSCO) has issued advisories to restrict the direct promotion of these drugs. The Union health ministry has also released a cautionary note emphasizing that these medications must be used under strict medical supervision to avoid potential risks.
Despite these regulatory efforts, analysts suggest that the growth trajectory of the GLP-1 segment is unlikely to be derailed. The high demand for effective weight-management tools means that while regulations may refine how the drugs are sold, they are unlikely to stop the momentum of generic adoption.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the guidance of a qualified healthcare provider regarding any medical condition or treatment.
As the market continues to evolve, the next critical milestone will be the potential entry of more tirzepatide generics and further pricing adjustments from global drugmakers. Industry observers will be watching the next quarter’s PharmaTrac data to see if Mounjaro can stabilize its value share or if the generic wave will lead to a total restructuring of the obesity drug market in India.
We invite you to share your thoughts on the accessibility of these treatments in the comments below or share this story with your professional network.
